# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Phillis Wheatley (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN015-SYN-TD
- Date: 1773-10-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Abena Hartley-Okonkwo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Asthma review five weeks after an exacerbation with a cold. **S**

## History of present illness

Miss Wheatley returns five weeks after the sick visit for asthma with a cold, when she stepped up to budesonide-formoterol as maintenance and reliever. The nurse telephoned her two days later and she was improving; she did not come for the review booked within a week, because she was very busy after her return. She never needed the standby prednisone. Her cold cleared within ten days; she now takes one inhalation twice daily and needs an extra one about once a week, and has not woken at night for three weeks. Her peak flow is 370 to 390 L/min. The screening tests from her preventive visit were negative for HIV, hepatitis C and hepatitis B surface antigen, and she has no immunity to hepatitis B. She has news she wanted to share: she now holds her own papers and her freedom, and whatever she earns from her book is her own. For now she still lives in the same house. **S**

| Element | Detail |
|---|---|
| Control | Asthma Control Test 20; extra reliever about once a week; no night waking for three weeks |
| After the exacerbation | Nurse call on day two; review within a week missed; no oral corticosteroid needed |
| Screening results | HIV, hepatitis C antibody and hepatitis B surface antigen negative; hepatitis B surface antibody negative |
| Circumstances | Now free, with her own papers and her own earnings |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Negative | No night waking; extra reliever about once a week |
| Ears, nose, mouth, and throat | Negative | Cold resolved; no hoarseness or thrush |
| Constitutional | Negative | Energy back; weight 47.6 kg |
| Psychiatric | Negative | Hopeful and busy; PHQ-2 0 |

4 systems reviewed. **S**

## Current medications

- Folic acid 0.4 mg oral tablet, one tablet daily **S**
- Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one inhalation as needed, no more than 12 inhalations a day **S**

## Allergies

- No known allergy **S**

## Objective

BP 104/66 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 99% on room air; weight 47.6 kg; BMI 20.6 kg/m². All vital signs are synthetic.

Asthma Control Test: 20; FEV1 before bronchodilator: 2.45 L; FEV1 percent predicted before bronchodilator: 91%; FEV1/FVC before bronchodilator: 0.78; FeNO: 24 [ppb]; Peak expiratory flow: 385 L/min; PHQ-2: 0. All results are synthetic.

## Change since baseline

- Asthma Control Test: 15 at baseline, 20 at this visit **S**
- PHQ-2: 1 at baseline, 0 at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**
- Human papillomavirus vaccine (9-valent), dose 2 of 3 **S**
- Influenza vaccine, the new season **S**
- COVID-19 mRNA vaccine, the new season's formula **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; oxygen saturation 99 percent; peak flow 385 L/min |
| Head, eyes, ears, nose, and throat | No oral thrush |
| Respiratory | Clear |
| Inhaler technique | Correct with the spacer |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Asthma, controlled on maintenance and reliever** (J45.30). Recovered from the exacerbation without an oral corticosteroid; FEV1 2.45 L (91 percent predicted), FEV1/FVC 0.78 and FeNO 24 ppb are now normal. Her summer away was free of trouble, and colds in cold, damp weather are her main risk, so she stays on maintenance and reliever through the winter and steps back down to as-needed treatment in the spring if she stays well. **S**
   - Continue budesonide-formoterol one inhalation twice daily and as needed.
   - Action plan updated for the winter.
   - Influenza and COVID-19 vaccines for the new season today.
   - Review in three months; consider stepping down in the spring.
2. **Asthma exacerbation with a cold** (J45.31). Resolved. **S**
   - Problem resolved; the standby prednisone, never used, is stopped and a new course will be written if needed.
3. **Seasickness** (T75.3XXA). Meclizine helped in the first days at sea and was finished on her return. **S**
   - Problem resolved.
4. **Vaccines and screening**. Not immune to hepatitis B; other screening negative. **S**
   - HepB-CpG dose 2 today completes the hepatitis B series.
   - HPV dose 2 today, delayed by her travel; dose 3 in about three months.
5. **Her changed circumstances**. She is now free and responsible for her own living. Her care, her information and her decisions remain hers, as before. **S**
   - Social work appointment, at her request, for health coverage in her own name, income and housing.
   - She will tell the clinic if her address or contact details change.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Asthma Control Test, symptoms, night waking and reliever use | Every visit | Completed today | Asthma Control Test 20; extra reliever about once a week; no night waking |
| Imaging | Spirometry and FeNO | Three to six months after starting treatment and after an exacerbation | Completed today | FEV1 2.45 L (91 percent); FEV1/FVC 0.78; FeNO 24 ppb |
| Imaging | Peak flow | Every visit and at home | Completed today | 385 L/min, green zone |
| Examination | Inhaler technique with her own inhaler, and adherence | Every visit; before any step-up | Completed today | Correct with the spacer; maintenance doses taken by the dose counter |
| Self-management | Written asthma action plan | Every visit and after every exacerbation | Completed today | Updated for maintenance and reliever through the winter |
| Self-management | Exacerbation history (oral corticosteroid courses, emergency visits, admissions) | Every visit | Completed today | One exacerbation in the past year, with a cold, managed without an oral corticosteroid or emergency care |
| Self-management | Review within a week of an exacerbation | Within one to seven days after any exacerbation | Deferred | Missed: the nurse telephoned on day two, but she did not attend the review booked within a week because she was busy after her return. No harm resulted: she recovered without an oral corticosteroid and her lung function is normal today. Corrective action: the clinic now offers a telephone or video review on the fifth to seventh day when an in-person visit is not kept, and she agreed to that for any future exacerbation |
| Self-management | Step-up or step-down assessment (GINA track 1) | Every visit | Completed today | Stepped to step 3 maintenance and reliever after the exacerbation; continue through the winter; step-down in the spring |
| Self-management | Triggers, exposures and smoking or vaping | Every visit | Completed today | Colds and cold, damp air; kitchen fan and open window; no smoke exposure |
| Survey | Depression screen | Yearly and when circumstances change | Completed today | PHQ-2 0 |
| Self-management | Vaccinations | Yearly | Completed today | Influenza and COVID-19 for the new season; hepatitis B series completed; HPV dose 2 of 3 |
| Referral | Biologic assessment | When asthma is severe or uncontrolled despite optimized step 4 to 5 treatment | Not indicated | Mild asthma controlled at step 3 |
| Self-management | Private conversation: consent, safety and exploitation, and her own decisions | Every visit | Completed today | Seen alone; she reports her freedom; social work booked at her request |

## Goal progress

- A confirmed diagnosis within two weeks: spirometry with bronchodilator response and FeNO, with tuberculosis excluded. Outcome by 1773-02-23: Asthma confirmed by a 330 mL (15 percent) bronchodilator response and FeNO 38 ppb; tuberculosis test negative and chest X-ray clear, two weeks after the first visit. **S**
- Asthma Control Test 20 or more with no night waking. Outcome by 1773-04-06: Asthma Control Test 21 and no night waking six weeks after starting treatment; 20 after the exacerbation. **S**
- Correct inhaler technique and a written action plan she can use at home and at sea. Outcome by 1773-04-06: Technique correct at every visit; plan used during the exacerbation. **S**
- Well enough to make the sea journey and spend the summer away. Outcome by 1773-09-21: Travelled and stayed well all summer without the standby prednisone. **S**
- No exacerbation needing an oral corticosteroid. Outcome by 1773-10-26: Achieved: one exacerbation with a cold, managed with extra budesonide-formoterol and a step-up, without prednisone. **S**
- Hepatitis B and HPV vaccination complete. In progress; target 1774-01-25. **S**

## Medication changes

- Stopped: Prednisone 20 mg oral tablet, standby course for the sea journey and the summer away: two tablets (40 mg) each morning for five days, to start only as her action plan directs **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026), Aether Forge
- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)
- Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023), American Thoracic Society
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Asthma review in three months, sooner in the yellow zone. HPV dose 3 in about three months. Social work appointment next week. Preventive visit in the spring. **S**

